AlignRT for intracranial stereotactic radiosurgery (MIB147)Product type:AdviceProgramme:Medtech innovation briefingPublished: 16 May 2018
Artificial intelligence for analysing CT brain scans (MIB207)Product type:AdviceProgramme:Medtech innovation briefingPublished: 17 March 2020
Asunercept for treating glioblastoma [1301]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Brain tumours (primary) and brain metastases in over 16s (NG99)Product type:GuidanceProgramme:NICE guidelineLast updated: 29 January 2021Published: 11 July 2018
Brain tumours (primary) and brain metastases in over 16s (QS203)Product type:Quality standardPublished: 7 December 2021
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2007
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
DCVax-L for treating glioblastoma [ID836]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Endoscopic transsphenoidal pituitary adenoma resection (IPG32)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 17 December 2003
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 March 2016Published: 26 April 2001
Improving outcomes for people with brain and other central nervous system tumours (CSG10)Product type:GuidanceProgramme:Cancer service guidelinePublished: 28 June 2006
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Photodynamic therapy for brain tumours (IPG290)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 March 2009
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 7 April 2025Published: 23 June 2015
Suspected neurological conditions: recognition and referral (NG127)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 1 May 2019
Suspected neurological conditions: recognition and referral (QS198)Product type:Quality standardPublished: 8 January 2021
Tovorafenib for Glioma (rare disease) [TSID12140]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025